Immunogenicity of the tuberculosis vaccine MVA85A is reduced by coadministration with EPI vaccines in a randomized controlled trial in Gambian infants.

Immunogenicity of the tuberculosis vaccine MVA85A is reduced by coadministration with EPI vaccines in a randomized controlled trial in Gambian infants.

Zobrazit další vydání (1)

New tuberculosis vaccines are urgently needed to curtail the current epidemic. MVA85A is a subunit vaccine that could enhance immunity from BCG vaccination. To determine MVA85A safety and immunogenicity as well as interactions with other routine vaccines administered in infancy, we randomized health...

Podrobná bibliografie
Hlavní autoři:	Ota, M, Odutola, A, Owiafe, P, Donkor, S, Owolabi, O, Brittain, N, Williams, N, Rowland-Jones, S, Hill, A, Adegbola, R, McShane, H
Médium:	Journal article
Jazyk:	English
Vydáno:	2011

Podobné jednotky

Immunogenicity of the Tuberculosis Vaccine MVA85A Is Reduced by Coadministration with EPI Vaccines in a Randomized Controlled Trial in Gambian Infants
Autor: Ota, M, a další
Vydáno: (2011)

A new TB vaccine, MVA85A, induces durable antigen-specific responses 14 months after vaccination in African infants
Autor: Odutola, A, a další
Vydáno: (2012)

A new TB vaccine, MVA85A, induces durable antigen-specific responses 14 months after vaccination in African infants.
Autor: Odutola, A, a další
Vydáno: (2012)

Safety and immunogenicity of the candidate tuberculosis vaccine MVA85A in West Africa.
Autor: Brookes, R, a další
Vydáno: (2008)

Safety and immunogenicity of the candidate tuberculosis vaccine MVA85A in West Africa.
Autor: Roger H Brookes, a další
Vydáno: (2008-08-01)

Correction: Safety and Immunogenicity of the Candidate Tuberculosis Vaccine MVA85A in West Africa.
Autor: Roger H. Brookes, a další
Vydáno: (2011-01-01)

A review of the tolerability of the candidate TB vaccine, MVA85A compared with BCG and Yellow Fever vaccines, and correlation between MVA85A vaccine reactogenicity and cellular immunogenicity
Autor: Rowland, R, a další
Vydáno: (2012)

Effect of vaccine dose on the safety and immunogenicity of a candidate TB vaccine, MVA85A, in BCG vaccinated UK adults
Autor: Pathan, A, a další
Vydáno: (2012)

Effect of vaccine dose on the safety and immunogenicity of a candidate TB vaccine, MVA85A, in BCG vaccinated UK adults.
Autor: Pathan, A, a další
Vydáno: (2012)

Comparing the safety and immunogenicity of a candidate TB vaccine MVA85A administered by intramuscular and intradermal delivery
Autor: Meyer, J, a další
Vydáno: (2013)

Safety and immunogenicity of boosting BCG vaccinated subjects with BCG: comparison with boosting with a new TB vaccine, MVA85A.
Autor: Whelan, K, a další
Vydáno: (2009)

Differential cytokine levels in adults induced by a Novel candidate TB boost vaccine, MVA85A-according to previous BCG vaccination status
Autor: Owiafe, P, a další
Vydáno: (2012)

Early clinical trials with a new tuberculosis vaccine, MVA85A, in tuberculosis-endemic countries: issues in study design.
Autor: Ibanga, H, a další
Vydáno: (2006)

Comparing the safety and immunogenicity of a candidate TB vaccine MVA85A administered by intramuscular and intradermal delivery.
Autor: Meyer, J, a další
Vydáno: (2013)

Safety and immunogenicity of the malaria candidate vaccines FP9 CS and MVA CS in adult Gambian men.
Autor: Imoukhuede, E, a další
Vydáno: (2006)

Evaluation of the safety and immunogenicity of a candidate tuberculosis vaccine, MVA85A, delivered by aerosol to the lungs of macaques.
Autor: White, A, a další
Vydáno: (2013)

Comparison of the safety and immunogenicity of a candidate TB vaccine, MVA85A, given by the intramuscular or intradermal route in BCG-vaccinated adults
Autor: Harris, S, a další
Vydáno: (2011)

Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in Mycobacterium tuberculosis-infected individuals.
Autor: Sander, C, a další
Vydáno: (2009)

Correction: Safety and Immunogenicity of Boosting BCG Vaccinated Subjects with BCG: Comparison with Boosting with a New TB Vaccine, MVA85A.
Autor: Kathryn T. Whelan, a další
Vydáno: (2011-01-01)

Safety and immunogenicity of malaria vectored vaccines given with routine EPI vaccines in Gambian infants and neonates: a randomized controlled trial
Autor: Mensah, V, a další
Vydáno: (2017)

DEVELOPING A NEW TB VACCINE: BOOSTING BCG WITH MVA85A
Autor: Mcshane, H
Vydáno: (2008)

Two doses of candidate TB vaccine MVA85A in antiretroviral therapy (ART) naive subjects gives comparable immunogenicity to one dose in ART+ subjects
Autor: Dieye, T, a další
Vydáno: (2013)

Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in healthy adults in South Africa.
Autor: Hawkridge, T, a další
Vydáno: (2008)

Safety and immunogenicity of a candidate tuberculosis vaccine MVA85A delivered by aerosol in BCG-vaccinated healthy adults: A phase 1, double-blind, randomised controlled trial
Autor: Satti, I, a další
Vydáno: (2014)

Correction: Safety and Immunogenicity of the Candidate Tuberculosis Vaccine MVA85A in West Africa
Vydáno: (2011-01-01)

Safety and immunogenicity of an FP9-vectored candidate tuberculosis vaccine (FP85A), alone and with candidate vaccine MVA85A in BCG-vaccinated healthy adults: a phase I clinical trial.
Autor: Rowland, R, a další
Vydáno: (2013)

Effects of MVA85A vaccine on tuberculosis challenge in animals: systematic review
Autor: Mcshane, H, a další
Vydáno: (2016)

A Phase I study evaluating the safety and immunogenicity of MVA85A, a candidate TB vaccine, in HIV-infected adults
Autor: Minassian, A, a další
Vydáno: (2011)

Dose-finding study of the novel tuberculosis vaccine, MVA85A, in healthy BCG-vaccinated infants.
Autor: Scriba, T, a další
Vydáno: (2011)

The effect of current Schistosoma mansoni infection on the immunogenicity of a candidate TB vaccine, MVA85A, in BCG-vaccinated adolescents: An open-label trial
Autor: Wajja, A, a další
Vydáno: (2017)

The effect of current Schistosoma mansoni infection on the immunogenicity of a candidate TB vaccine, MVA85A, in BCG-vaccinated adolescents: An open-label trial.
Autor: Anne Wajja, a další
Vydáno: (2017-05-01)

Two doses of candidate TB vaccine MVA85A in antiretroviral therapy (ART) naïve subjects gives comparable immunogenicity to one dose in ART+ subjects.
Autor: Tandakha N Dieye, a další
Vydáno: (2013-01-01)

Improved adjuvanting of seasonal influenza vaccines: preclinical studies of MVA-NP+M1 coadministration with inactivated influenza vaccine.
Autor: Mullarkey, C, a další
Vydáno: (2013)

Evaluating aerosol administration of a candidate TB vaccine MVA85A
Autor: Thomas, Z, a další
Vydáno: (2014)

Correction: Two Doses of Candidate TB Vaccine MVA85A in Antiretroviral Therapy (ART) Naïve Subjects Gives Comparable Immunogenicity to One Dose in ART+ Subjects.
Autor: Tandakha N. Dieye, a další
Vydáno: (2013-01-01)

Safety and immunogenicity of a candidate tuberculosis vaccine MVA85A delivered by aerosol in BCG-vaccinated healthy adults: a phase 1, double-blind, randomised controlled trial.
Autor: Satti, I, a další
Vydáno: (2014)

Boosting BCG with MVA85A: the first candidate subunit vaccine for tuberculosis in clinical trials.
Autor: Mcshane, H, a další
Vydáno: (2005)

A first-in-human phase 1 trial to evaluate the safety and immunogenicity of the candidate tuberculosis vaccine MVA85A-IMX313, administered to BCG-vaccinated adults.
Autor: Minhinnick, A, a další
Vydáno: (2016)

The candidate TB vaccine, MVA85A, induces highly durable Th1 responses
Autor: Tameris, M, a další
Vydáno: (2014)

Th1/Th17 cell induction and corresponding reduction in ATP consumption following vaccination with the novel Mycobacterium tuberculosis vaccine MVA85A.
Autor: Griffiths, K, a další
Vydáno: (2011)